摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-{1-[3-(3,5-difluoro-4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one | 1448717-69-8

中文名称
——
中文别名
——
英文名称
2-{1-[3-(3,5-difluoro-4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one
英文别名
2-[1-[3-(3,5-difluoro-4-methoxyphenyl)azetidin-1-yl]ethyl]-7-(oxan-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one
2-{1-[3-(3,5-difluoro-4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one化学式
CAS
1448717-69-8
化学式
C22H25F2N5O3
mdl
——
分子量
445.469
InChiKey
MSRRZANNVJWURL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    32
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    81
  • 氢给体数:
    1
  • 氢受体数:
    8

文献信息

  • [EN] PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE<br/>[FR] INHIBITEURS DE PDE9 COMPRENANT UN SQUELETTE IMIDAZOTRIAZINONE
    申请人:LUNDBECK & CO AS H
    公开号:WO2013110768A1
    公开(公告)日:2013-08-01
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula(l) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种式(I)化合物,用于治疗患有精神障碍的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。
  • PDE9 inhibitors with imidazo triazinone backbone
    申请人:H. Lundbeck A/S
    公开号:US20150045348A1
    公开(公告)日:2015-02-12
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。
  • PDE9 Inhibitors with Imidazo Triazinone Backbone
    申请人:H. Lundbeck A/S
    公开号:US20160213674A1
    公开(公告)日:2016-07-28
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    本发明涉及一种PDE9酶抑制剂化合物。本发明提供一种制药组合物,包括本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备式(I)化合物的过程。本发明还提供了一种治疗神经退行性疾病的方法,包括向患者施用式(I)化合物的治疗有效量。本发明还提供了一种式(I)化合物,用于治疗精神障碍的方法,包括向患者施用式(I)化合物的治疗有效量。
  • PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE
    申请人:H. Lundbeck A/S
    公开号:EP2807163B1
    公开(公告)日:2017-03-22
  • PDE9- INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE
    申请人:H. Lundbeck A/S
    公开号:EP3178820B1
    公开(公告)日:2017-12-20
查看更多

同类化合物

阿法拉定A,TFA 钠咪唑并[1,2-a]吡啶-2-羧酸酯水合物(1:1:1) 钠(E)-2-氰基-3-[2,8-二(丙-2-基氧基)咪唑并[3,2-a]吡啶-3-基]丙-2-烯酸酯 诺白拉斯啶 苯酚,4-(5,6,7,8-四氢咪唑并[1,2-a]吡啶-8-基)- 米诺膦酸 米诺磷酸一水合物 硫酸利美戈潘 盐酸法屈唑半水合物 盐酸依格列汀 甲基咪唑并[1,5-A]吡啶-1-甲酸叔丁酯 甲基3-氨基咪唑并[1,2-a]吡啶-5-羧酸酯 甲基-(7-甲基咪唑并[1,2-A〕吡啶-2-基甲基)-胺 甲基-(5-甲基-咪唑并[1,2-A]吡啶-2-甲基)-胺 甲基 2-甲基咪唑并[1,2-a]吡啶-3-羧酸 环戊烷羧酸2-氨基-4-亚甲基-,(1R,2S)-(9CI) 环巴胺抑制剂1 泰妥拉唑 法倔唑盐酸盐 法倔唑 沃利替尼(对映异构体) 沃利替尼 氨基膦酸杂质14 戊酰胺,N-(2-丁基-1H-咪唑并[4,5-b]吡啶-6-基)- 巴马鲁唑 奥克塞米索 地扎胍宁甲磺酸盐 地扎胍宁 土大黄甙 咪唑磺隆 咪唑并吡啶-6-甲胺盐酸盐 咪唑并吡啶-2-酮盐酸盐 咪唑并吡啶-2-酮 咪唑并二甲基吡啶 咪唑并[2,1-a]异喹啉-2(3H)-酮 咪唑并[1,5-a]喹唑啉,6-氯-3-(3-环丙基-1,2,4-噁二唑-5-基)-5-(4-吗啉基)- 咪唑并[1,5-a]吡啶-8-胺 咪唑并[1,5-a]吡啶-8-羧酸乙酯 咪唑并[1,5-a]吡啶-8-甲醛 咪唑并[1,5-a]吡啶-7-羧酸甲酯 咪唑并[1,5-a]吡啶-7-羧酸乙酯 咪唑并[1,5-a]吡啶-6-羧酸甲酯 咪唑并[1,5-a]吡啶-6-羧酸乙酯 咪唑并[1,5-a]吡啶-5-胺 咪唑并[1,5-a]吡啶-5-羧酸甲酯 咪唑并[1,5-a]吡啶-5-羧酸乙酯 咪唑并[1,5-a]吡啶-5-甲醛 咪唑并[1,5-a]吡啶-3-羧酸乙酯 咪唑并[1,5-a]吡啶-3-磺酰胺 咪唑并[1,5-a]吡啶-3-甲醛